Wang, Fangfang
Liu, Zhiping
Niu, Xiaoye
Zhao, Lin
Zhu, Jixiang
Qi, Linjing
Liu, Lu
Liu, Ziyang
Sun, Yunan
Diao, Lei
Lu, Jun
Zhou, Yongchun
Wang, Xiaoye
Li, Haiyan http://orcid.org/0000-0002-8286-2813
Funding for this research was provided by:
Fosun Pharma
Article History
Accepted: 25 May 2023
First Online: 28 June 2023
Declarations
:
: These studies were funded by Wanbang Biopharmaceuticals.
: Lu Liu, Ziyang Liu, Yunan Sun, Lei Diao, and Jun Lu are full-time employees of Fosun Pharma. Yongchun Zhou is a full-time employee of Wanbang Biopharmaceuticals. Fangfang Wang, Zhiping Liu, Xiaoye Niu, Lin Zhao, Jixiang Zhu, Linjing Qi, Xiaoye Wang, and Haiyan Li have no conflicts of interest that are directly relevant to the content of this article.
: The protocols of two trials (CTR20213292 and CTR20213291) were approved by the Institutional Review Board of Peking University Third Hospital (Beijing, China). The studies were conducted in accordance with the 1964 Declaration of Helsinki and its later amendments and all Chinese regulatory requirements.
: Written informed consent was obtained from all subjects for these two studies before the screening.
: Not applicable.
: All data generated or analyzed during this study are included in this published article and its supplementary information files.
: Not applicable.
: Conceptualization: LD, JL, YZ, XW, and HL; methodology: LL and ZL; investigation: FW, ZL, XN, LZ, JZ, and LQ; formal analysis: YS; and writing (review and editing): FW, ZL, XN, LZ, JZ, LQ, LL, ZL, YS, LD, JL, YZ, XW, and HL.